​

Qualigen Therapeutics Stock (NASDAQ:QLGN)

OwnershipFinancialsChart
Qualigen Therapeutics by TradingView

Previous Close

$1.85

52W Range

$1.61 - $10.45

50D Avg

$2.38

200D Avg

$3.36

Market Cap

$3.54M

Avg Vol (3M)

$856.19K

Beta

-0.15

Div Yield

-

QLGN Company Profile

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jun 23, 2015

Website

QLGN Performance

QLGN Financial Summary

Dec 23Dec 22Dec 21
Revenue$5.20M$4.98M$5.65M
Operating Income$-11.30M$-17.94M$-22.66M
Net Income$-13.42M$-21.03M$-17.90M
EBITDA$-11.30M$-13.84M$-22.66M
Basic EPS$-2.46$-5.48$-6.10
Diluted EPS$-2.46$-5.48$-6.10

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q1 21Aug 18, 20 | 4:30 PM

Peer Comparison

TickerCompany
ADTXAditxt, Inc.
ARTLArtelo Biosciences, Inc.
ISPCiSpecimen Inc.
PTPIPetros Pharmaceuticals, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
SONNSonnet BioTherapeutics Holdings, Inc.
KTTAPasithea Therapeutics Corp.
ATHEAlterity Therapeutics Limited